These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 28223167

  • 1. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J, Maher J.
    Cancer Lett; 2017 May 01; 393():52-59. PubMed ID: 28223167
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
    Mayor M, Zeltsman M, McGee E, Adusumilli PS.
    Immunotherapy; 2016 May 01; 8(5):491-4. PubMed ID: 27140404
    [No Abstract] [Full Text] [Related]

  • 7. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S, Soltermann A, Jungraithmayr W, Eisenring M, Winder T, Samaras P, Tabor A, Stenger R, Stupp R, Weder W, Renner C, Münz C, Petrausch U.
    Clin Cancer Res; 2018 Aug 15; 24(16):3981-3993. PubMed ID: 29748183
    [Abstract] [Full Text] [Related]

  • 8. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
    Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.
    Cancer Res; 2010 Nov 15; 70(22):9053-61. PubMed ID: 20926399
    [Abstract] [Full Text] [Related]

  • 9. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q, Wang H, Li H, Xu J, Tian K, Yang J, Lu Z, Zheng J.
    Oncotarget; 2017 Feb 07; 8(6):9488-9499. PubMed ID: 28055955
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.
    Cancer Immunol Res; 2014 Feb 07; 2(2):112-20. PubMed ID: 24579088
    [Abstract] [Full Text] [Related]

  • 12. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
    Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM.
    Clin Cancer Res; 2011 Jul 15; 17(14):4719-30. PubMed ID: 21610146
    [Abstract] [Full Text] [Related]

  • 13. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z, Jiang J, Wu X, Zhang M, Luo D, Zhang R, Li S, He Y, Bian H, Chen Z.
    Front Med; 2019 Feb 15; 13(1):57-68. PubMed ID: 30721445
    [Abstract] [Full Text] [Related]

  • 14. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH, Stashwick C, Plesa G, Tanyi JL.
    Immunotherapy; 2017 Aug 15; 9(9):767-780. PubMed ID: 28771103
    [Abstract] [Full Text] [Related]

  • 15. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.
    Clin Cancer Res; 2014 Aug 15; 20(16):4262-73. PubMed ID: 24919573
    [Abstract] [Full Text] [Related]

  • 16. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
    Schutsky K, Song DG, Lynn R, Smith JB, Poussin M, Figini M, Zhao Y, Powell DJ.
    Oncotarget; 2015 Oct 06; 6(30):28911-28. PubMed ID: 26359629
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.
    Li H, Huang Y, Jiang DQ, Cui LZ, He Z, Wang C, Zhang ZW, Zhu HL, Ding YM, Li LF, Li Q, Jin HJ, Qian QJ.
    Cell Death Dis; 2018 Feb 07; 9(2):177. PubMed ID: 29415996
    [Abstract] [Full Text] [Related]

  • 18. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF, Turazzi N, Benedicenti F, Calabria A, Tenderini E, Tettamanti S, Giordano Attianese GM, Cooper LJ, Aiuti A, Montini E, Biondi A, Biagi E.
    Oncotarget; 2016 Aug 09; 7(32):51581-51597. PubMed ID: 27323395
    [Abstract] [Full Text] [Related]

  • 19. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
    Forsberg EMV, Lindberg MF, Jespersen H, Alsén S, Bagge RO, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA.
    Cancer Res; 2019 Mar 01; 79(5):899-904. PubMed ID: 30622115
    [Abstract] [Full Text] [Related]

  • 20. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
    Zeltsman M, Dozier J, McGee E, Ngai D, Adusumilli PS.
    Transl Res; 2017 Sep 01; 187():1-10. PubMed ID: 28502785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.